Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male or female subject, aged 18 to 65 years (inclusive) at screening
Stable therapeutic dose of the approved ADT throughout the study
Must not have
History of psychotic disorder, including but not limited to schizophrenia, MDD with psychotic features, or bipolar I/II disorder with and without psychotic features
Diagnosis within the last 12 months before screening or current diagnosis of PTSD, OCD, panic disorder, acute stress disorder, or has a history of intellectual disability, autism, or cluster A or B personality disorder
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 days
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new medication called SPN-820 to see if it helps adults with depression feel better when added to their current treatment.
Who is the study for?
Adults aged 18-65 with Major Depressive Disorder (MDD) as per DSM-5, having a current depressive episode without psychotic features. Participants must have been on a stable dose of certain antidepressants for at least 4 weeks. Excludes those with significant recent suicidal behavior or ideation, substance abuse history within the last 6 months, and other psychiatric disorders.
What is being tested?
The trial is testing SPN-820's effectiveness and safety in treating MDD. It involves adults who meet specific criteria related to their depression severity and treatment history.
What are the potential side effects?
While the side effects are not specified here, common ones for new antidepressant treatments can include nausea, headaches, sleep disturbances, agitation or anxiety, sexual dysfunction, and sometimes increased risk of suicidal thoughts.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 65 years old.
Select...
I am on a stable dose of hormone therapy for my condition.
Select...
I have been diagnosed with major depression without psychosis.
Select...
I am moderately ill or worse according to a CGI-S score.
Select...
My depression is severe, with a MADRS score of 22 or higher.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a history of a psychotic disorder such as schizophrenia or bipolar disorder.
Select...
I was diagnosed with PTSD, OCD, panic disorder, acute stress disorder, or have a history of intellectual disability, autism, or certain personality disorders within the last year.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 10 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Evaluation of the efficacy of SPN-820 administered once every 3 days as measured by the Hamilton Depression Rating Scale-6 Items
Secondary study objectives
Evaluation of the efficacy as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) score
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: SPN-820 6 x 400 mg capsulesExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NV-5138
2018
Completed Phase 1
~80
Find a Location
Who is running the clinical trial?
Navitor Pharmaceuticals, Inc.Lead Sponsor
3 Previous Clinical Trials
486 Total Patients Enrolled
2 Trials studying Depression
480 Patients Enrolled for Depression
Supernus Pharmaceuticals, Inc.Industry Sponsor
47 Previous Clinical Trials
13,734 Total Patients Enrolled
1 Trials studying Depression
400 Patients Enrolled for Depression
Share this study with friends
Copy Link
Messenger